

Clinical Trials Advisory and Awards Committee (CTAAC)

Supplementary Terms of Reference

- 1 **Remit:** the Clinical Trials Advisory and Awards Committee is a sub-committee of the Clinical and Translational Research Committee (CTRC) with a remit to review and fund prospective cancer clinical trials and meta-analyses. This includes phase I/II or feasibility studies and phase III/IV therapeutic, diagnostic or chemoprevention trials and associated sample collections. In addition, to peer review proposals for company funded (primarily University/Trust sponsored) phase III clinical trials. Both of these to result in a national portfolio of high quality academic clinical trials. In fulfilment of this, CTAAC will work with:
 - Cancer Research UK's Clinical and Translational Research Committee (CTRC) and where appropriate other Funding Committees, to ensure co-ordination of activities and appropriate input to the development of strategies and policies on clinical trials.
 - Appropriate Committees or panels, partner funders such as Medical Research Council, Health Technology Assessment, National Institute for Health Research and Leukaemia Research Fund.
 - The NCRI and NCRN, including the site specific and cross-cutting NCRI Clinical Studies Groups.

- 2 **Additional Terms:**
 - 2.1 To review outline and full applications, on behalf of Cancer Research UK, for all phase III clinical trials and sample collections, including some primary prevention trials involving medical interventions (e.g. chemoprevention or vaccines) and some secondary prevention trials (e.g. use of aspirin in patients with colorectal polyps).
 - 2.2 To review phase I/II or feasibility studies using a single-stage application process.
 - 2.3 To ensure written confirmation of the 'Sponsor' for the trial, as required under the EU Clinical Trials Directive (2001/20/EC-[EUCTD]), and or the Department of Health Research Governance, before funding/endorsement is provided in line with CR-UK Clinical Trials Policy. The Charity will not act as Sponsor for any trials funded or approved via this funding scheme.
 - 2.4 To liaise with the Biomarkers and Imaging Discovery and Development Committee (BIDD) with regards to applications for translational research associated with clinical trials.
 - 2.5 To consider and have in place mechanisms for the dissemination of information both internally and externally on the impact of study outcomes.

3 Membership:

- The Chairman of CTAAC will be independent from Cancer Research UK and a non-oncologist.
- There will be three Vice-Chairs, who will be oncologists and will have complementary expertise.
- Additional external members will ensure that the committee has standing expertise in areas pertinent to academic cancer clinical trial research, including surgery, medical and clinical oncology, medical statistics, and clinical trials.
- There will be two independent members, including one consumer. An NRCN observer will also be invited.
- An international panel of experts will review outline and feasibility applications.

4 Meetings: the Committee will normally meet three times a year.